MeiraGTx Holdings PLC (MGTX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$8.75
Buy
$9.50
$0.20 (+2.29%)
Prices updated at 12 Dec 2025, 22:48 EST
| Prices minimum 15 mins delay
Prices in USD
MeiraGTx Holdings PLC is a clinical stage gene therapy company. Its pipeline products include AAV-CNGB3, AAV-CNGA3. AAV-UPF1, West AMD, Dry AMD, and others. Geographically, the company generates a majority of its revenue from the United Kingdom.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | 28.51 |
| 2023 | 100.00 |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 26.01 |
| 2024 | 28.69 |
| 2023 | 55.22 |
| 2022 | 6.87 |
| 2021 | 50.03 |
| 2020 | 29.75 |
| 2019 | 97.01 |
| 2018 | - |
Price/Forward earnings (YTD)
-6.71
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | -49.55 |
| 2023 | -26.06 |
| 2022 | -40.61 |
| 2021 | -23.27 |
| 2020 | -16.87 |
| 2019 | -26.02 |
| 2018 | -137.96 |
| 2017 | -131.60 |
| 2016 | -86.79 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 3.98 |
| 2023 | 2.36 |
| 2022 | 2.70 |
| 2021 | 1.73 |
| 2020 | 1.52 |
| 2019 | 1.70 |
| 2018 | 1.20 |
| 2017 | - |
| 2016 | - |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
